Method of treating a brain tumor
Disclosed herein are methods of treating a brain tumor by administering Plinabulin. Some embodiments relate to treatment of glioblastoma multiforme by administering Plinabulin.
1. A method of therapeutically treating a brain tumor comprising administering an effective amount of plinabulin to a subject in need thereof, wherein the brain tumor is metastatic brain tumor, anaplastic astrocytoma, glioblastoma multiforme, oligodendroglioma, ependymomas, or a combination thereof.
2. The method of claim 1 , wherein the brain tumor is a glioblastoma multiforme.
3. The method of claim 1 , wherein the brain tumor is a metastatic brain tumor.
4. The method of claim 1 , further comprising administering an additional therapeutic agent.
5. The method of claim 4 , wherein the additional therapeutic agent is temozolomide.
6. The method of claim 1 , further comprising subjecting the subject to radiation therapy.
7. The method of claim 1 , wherein the brain tumor is characterized by expression of a mutant form of KRAS.
8. A method of inhibiting proliferation of brain tumor cell, comprising contacting the brain tumor cell with plinabulin, wherein the brain tumor is metastatic brain tumor, anaplastic astrocytoma, glioblastoma multiforme, oligodendroglioma, ependymomas, or a combination thereof.
9. The method of claim 8 , wherein contacting comprises administering an effective amount of plinabulin to a subject having the brain tumor cell.
10. A method of inducing apoptosis in brain tumor cell, comprising contacting the brain tumor cell with plinabulin, wherein the brain tumor is metastatic brain tumor, anaplastic astrocytoma, glioblastoma multiforme, oligodendroglioma, ependymomas, or a combination thereof.
11. The method of claim 10 , wherein contacting comprises administering an effective amount of plinabulin to a subject having the brain tumor cell.
12. The method of claim 1 , wherein the plinabulin is administered once a week.
13. The method of claim 1 , wherein the plinabulin is administered once on each of day 1 and day 8 of a three-week (21 day) treatment cycle.
14. The method of claim 4 , wherein the additional therapeutic agent is selected from the group consisting of temozolomide, bevicizumab, everolimus, carmustine, lomustine, procarbazine, vincristine, irinotecan, cisplatin, carboplatin, methatrexate, etoposide, vinblasatine, bleomycin, actinomycin, cyclophosphamide, and ifosfamide.
15. The method of claim 4 , wherein the additional therapeutic agent is lomustine.
16. The method of claim 1 , wherein a single dose of plinabulin is in the range of 5 mg/m 2 to about 150 mg/m 2 of body surface area.
17. The method of claim 1 , wherein a single dose of plinabulin is in the range of about 13.5 mg/m 2 to about 30 mg/m 2 of body surface area.
18. The method of claim 1 , wherein the plinabulin is administered parenterally.
19. The method of claim 6 , wherein the radiation therapy is selected from whole-brain irradiation, fractionated radiotherapy, radio surgery, and a combination thereof.